What the Biggest Investors Are Doing About Opko Health Stock's Dismal Performance
So far in 2017, Opko Health (NASDAQ: OPK) has lost roughly one-third of its market cap. The stock finished 2016 down 7% due to an end-of-year plunge.
Things aren't going well for multiple reasons. That big drop at the end of last year stemmed from disappointing results from a late-stage study of Opko's experimental long-acting human growth hormone product (hGH-CTP) in adults. The company's 2015 acquisition of Bio-Reference Labs still doesn't appear to be paying off. The launch for its secondary hyperparathyroidism (SHPT) drug Rayaldee has been sluggish.
Around 17% of Opko Health stock is owned by institutions and funds. With all of the company's woes, what are these big investors doing about Opko?
Source: Fool.com
Blackrock Inc. Stock
€796.80
1.150%
With 15 Buy predictions and not the single Sell prediction the community is currently very high on Blackrock Inc..
As a result the target price of 851 € shows a slightly positive potential of 6.8% compared to the current price of 796.8 € for Blackrock Inc..
